HF-REVERT
Phase 2, Multicentre, Randomised, Double-blind, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial Infarction
- Stadium
- klaar
- Middel
- CDR132L
- Populatie
- ASCVD
- Fase
- II
- First Patient In
- 30 juni 2022
- Last Patient In
- 4 maart 2024
- Last Patient Last Visit
- 17 maart 2025
National Lead
prof. dr. R.A. de Boer
Cardioloog
Studiedirecteur
dr. T. Oosterhof
Cardioloog
Contact Kantoor
